Abstract PD4-07: Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study
Conclusions: The occurrence of MI is very low in this cohort (4.4%), reassuring the clinicians that the older adults with comorbidities may not be at a higher risk of MI with adjuvant endocrine therapy. However, the confidence interval for the hazard ratio of AIs vs Tamoxifen is very wide, indicating that a larger sample may be needed for the power of the study to be conclusive.Citation Format: Kamaraju S, Smith E, Shi Y, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD4-07.
Source: Cancer Research - Category: Cancer & Oncology Authors: S Kamaraju, E Smith, Y Shi, P Laud, J Neuner Tags: Poster Discussion Abstracts Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Congestive Heart Failure | Databases & Libraries | Diabetes | Endocrine Therapy | Endocrinology | Epidemiology | Heart | Heart Attack | Heart Disease | Heart Failure | Hypertension | ICD-10 | Medicare | Men | Menopause | Peripheral Vascular Disease (PVD) | Stroke | Study | Tamoxifen | Women